{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-007924","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.913610+00:00","generated_at":"2026-06-08T04:48:17.468625+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sunshine Biopharma Q3 2023 revenues surge to $5.96M on Nora Pharma acquisition; net loss narrows to $0.04/sh","bullets":["Gross revenues $5,957,668 for Q3 2023, up from $132,808 a year earlier, driven by Nora Pharma Inc. acquisition.","Net loss from operations narrowed to $651,482 ($0.04 per share) from $1,457,019 ($0.12 per share) in Q3 2022.","Sequential revenue growth: 7.1% from Q2 2023 ($5,560,865) and 21.7% from Q1 2023 ($4,894,053).","CEO Steve Slilaty stated focus on cost cutting and reaching profitability as key goals going forward."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-007924","json":"https://secwatch.observer/filing/0001683168-23-007924.json","markdown":"https://secwatch.observer/filing/0001683168-23-007924.md","text":"https://secwatch.observer/filing/0001683168-23-007924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823007924/0001683168-23-007924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823007924/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:48:17.468625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a2df91180ca3806d8e803f56e02a7884ef554f7","claim":"Sunshine Biopharma Inc. reported the quarter ended September 30, 2023 results: revenue $5,957,668, net income net loss of $651,482 ($0.04 per share).","evidence_excerpt":"Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 third quarter. The Company reported gross revenues of $5,957,668 for the quarter ended September 30, 2023, an increase of $5,824,860 over the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823007924/0001683168-23-007924-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$5,957,668"},{"label":"Net income","value":"net loss of $651,482 ($0.04 per share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}